Lee S C, Yoburn B C
Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.
Pharmacol Biochem Behav. 2000 Jun;66(2):347-51. doi: 10.1016/s0091-3057(00)00170-2.
Regulation of calcium flux has been suggested to play a role in acute and chronic effects of opioids. Previous studies have shown calcium channel blockers can inhibit opioid agonist-induced downregulation of mu-opioid receptors and may reduce the magnitude of tolerance. In the present study, we determined if calcium channel blockade would affect increases in opioid receptor density and functional supersensitivity produced by chronic opioid antagonist treatment in the mouse. Mice were implanted subcutaneously with a 15-mg naltrexone (NTX) or placebo pellet. Mice also were implanted with an osmotic minipump that infused nimodipine (100 microg/kg/day) or a second placebo pellet. This protocol yielded four groups: nimodipine-NTX; nimodipine-placebo; placebo-NTX; placebo-placebo. On the seventh day, pumps and pellets were removed. Twenty-four hours later, a morphine dose-response study was conducted (tail flick); or mice were sacrificed and saturation binding studies ([3H]DAMGO) were performed in whole brain. NTX treatment significantly increased the analgesic potency of morphine by approximately 60%. Nimodipine increased the potency of morphine by approximately 50%. For mice treated with both nimodipine and NTX, there was an additive effect on morphine potency ( approximately 120% increase). In binding studies, NTX increased the density of mu-opioid receptors similarly ( approximately 60-70%) in the presence and absence of nimodipine treatment, with no change in affinity. No effect of chronic nimodipine alone on mu-opioid receptor binding was observed. These data indicate that NTX-induced upregulation and supersensitivity are independent of calcium channel blockade by nimodipine. These results contrast with those from tolerance and downregulation studies, and confirm suggestions that different substrates mediate chronic opioid agonist and antagonist-induced effects in vivo. Finally, in a separate study, morphine potency was unaffected by acute nimodiopine (100 microg/kg; SC), suggesting that prolonged exposure to this calcium channel blocker is required to increase morphine potency.
钙通量调节被认为在阿片类药物的急性和慢性效应中起作用。先前的研究表明,钙通道阻滞剂可抑制阿片类激动剂诱导的μ-阿片受体下调,并可能降低耐受性的程度。在本研究中,我们确定钙通道阻滞是否会影响慢性阿片类拮抗剂治疗在小鼠中产生的阿片受体密度增加和功能超敏反应。将小鼠皮下植入15毫克纳曲酮(NTX)或安慰剂药丸。小鼠还植入了渗透微型泵,该泵注入尼莫地平(100微克/千克/天)或第二颗安慰剂药丸。该方案产生了四组:尼莫地平-NTX;尼莫地平-安慰剂;安慰剂-NTX;安慰剂-安慰剂。在第七天,取出泵和药丸。24小时后,进行吗啡剂量反应研究(甩尾法);或者处死小鼠并在全脑中进行饱和结合研究([3H]DAMGO)。NTX治疗使吗啡的镇痛效力显著提高约60%。尼莫地平使吗啡的效力提高约50%。对于同时接受尼莫地平和NTX治疗的小鼠,对吗啡效力有相加作用(约增加120%)。在结合研究中,无论是否有尼莫地平治疗,NTX均使μ-阿片受体密度类似地增加(约60-70%),亲和力无变化。未观察到单独慢性使用尼莫地平对μ-阿片受体结合有影响。这些数据表明,NTX诱导的上调和超敏反应与尼莫地平的钙通道阻滞无关。这些结果与耐受性和下调研究的结果形成对比,并证实了不同底物介导体内慢性阿片类激动剂和拮抗剂诱导效应的观点。最后,在一项单独的研究中,急性尼莫地平(100微克/千克;皮下注射)对吗啡效力无影响,这表明需要长期接触这种钙通道阻滞剂才能提高吗啡效力。